Table 3 Risk factors for receiving ASM therapy among epileptic patients on continuous ASM treatment (n = 569 a)
Valproate OR (95% CI) | Levetiracetam OR (95% CI) | Lamotrigine OR (95% CI) | Carbamazepine OR (95% CI) | Oxcarbazepine OR (95% CI) | |
|---|---|---|---|---|---|
Age | |||||
<16Y | 0.72 (0.32–1.61) | 7.5 (2.61–21.77) | 3.60 (0.73–18.09) | 0.16 (0.03–0.90) | 0.17 (0.06–0.46) |
16-60Y | 0.92 (0.46–1.87) | 2.11 (0.77–5.78) | 5.21 (1.18–22.96) | 0.84 (0.30–2.35) | 0.29 (0.13–0.65) |
≥ 60Y | 1 | 1 | 1 | 1 | 1 |
Gender | |||||
male | 1.31 (0.88–1.93) | 0.79 (0.51–1.23) | 0.45 (0.27–0.75) | 0.98 (0.57–1.69) | 0.87 (0.49–1.56) |
female | 1 | 1 | 1 | 1 | 1 |
Education level | |||||
Primary school | 2.16 (0.97–4.79) | 0.41 (0.18–0.93) | 0.49 (0.18–1.32) | 0.61 (0.21–1.77) | 2.51 (0.81–7.79) |
High school | 2.32 (1.22–4.39) | 0.43 (0.23–0.79) | 0.59 (0.31–1.16) | 1.03 (0.49–2.18) | 1.24 (0.47–3.24) |
Bachelor’s degree and above | 1 | 1 | 1 | 1 | 1 |
Residence | |||||
Urban | 1.06 (0.71–1.59) | 0.72 (0.45–1.15) | 1.11 (0.64–1.94) | 1.13 (0.63–1.99) | 0.80 (0.43–1.49) |
Rural | 1 | 1 | 1 | 1 | 1 |
Household income (Yuan/year) | |||||
< 60,000 | 1.93 (1.27–2.93) | 0.62 (0.39–0.98) | 0.73 (0.43–1.24) | 3.19 (1.73–5.93) | 1.21 (0.66–2.26) |
≥ 60,000 | 1 | 1 | 1 | 1 | 1 |
Hospital | |||||
Junior | 0.13 (0.04–0.42) | 0.05 (0.01–0.37) | 0 (0–0) | 4.33 (2.03–9.25) | 0 (0–0) |
Middle | 0.74 (0.37–1.46) | 0.15 (0.03–0.62) | 0.18 (0.04–0.78) | 5.13 (2.47–10.63) | 0.44 (0.13–1.53) |
Senior | 1 | 1 | 1 | 1 | 1 |